Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis

NCT03055195 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03055195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03055195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2017
Completion date
December 6, 2017
Enrollment
34 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic